REGENXBIO (NASDAQ:RGNX) Insider Steve Pakola Sells 5,124 Shares

REGENXBIO Inc. (NASDAQ:RGNX) insider Steve Pakola sold 5,124 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $10.35, for a total transaction of $53,033.40. Following the completion of the sale, the insider directly owned 247,926 shares of the company’s stock, valued at approximately $2,566,034.10. This trade represents a 2.02% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

REGENXBIO Stock Performance

Shares of REGENXBIO stock traded down $0.68 during trading hours on Friday, hitting $8.41. The company’s stock had a trading volume of 643,156 shares, compared to its average volume of 1,023,907. The business has a 50 day moving average price of $11.10 and a two-hundred day moving average price of $11.43. REGENXBIO Inc. has a 12-month low of $5.03 and a 12-month high of $16.19. The company has a market cap of $433.78 million, a PE ratio of -2.23 and a beta of 1.08.

REGENXBIO (NASDAQ:RGNX) last posted its quarterly earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.29). REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%.The business had revenue of $30.34 million during the quarter, compared to the consensus estimate of $45.48 million. As a group, research analysts anticipate that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have commented on RGNX shares. Weiss Ratings reissued a “sell (d-)” rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Robert W. Baird set a $27.00 target price on shares of REGENXBIO in a research note on Tuesday, February 10th. The Goldman Sachs Group reduced their price objective on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a report on Tuesday, February 10th. Stifel Nicolaus boosted their price target on shares of REGENXBIO from $40.00 to $45.00 and gave the company a “buy” rating in a report on Friday, December 19th. Finally, Leerink Partners boosted their price target on REGENXBIO from $16.00 to $20.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $27.50.

Key Stories Impacting REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Positive clinical data and safety signals for RGX‑202 from the Phase 1/2 AFFINITY Duchenne program — interim efficacy signals reported and company statements indicating no evidence of liver injury in the study, supporting the program’s safety profile. AFFINITY interim data Safety: no liver injury
• Neutral Sentiment: Insider transaction: Director/officer Steve Pakola sold 5,124 shares on March 10 at about $10.35 (disclosed 3/12). The sale is small (~2% reduction of his position) but attracts attention given current volatility. SEC filing
• Neutral Sentiment: Market reaction described as “mixed signals” by coverage — clinical progress noted but shares have moved downward amid other news flow. This commentary helps explain intraday weakness. Benzinga: mixed signals
• Negative Sentiment: Multiple law firms have filed or are soliciting class-action claims against REGENXBIO for alleged securities violations covering purchases from Feb. 9, 2022 to Jan. 27, 2026, and are seeking lead plaintiffs (April 14, 2026 deadline). The proliferation of filings increases potential legal/settlement risk and creates headline pressure. GlobeNewswire: Schall Law Firm
• Negative Sentiment: Analyst headwind: HC Wainwright published a bearish forecast for RGNX Q1 earnings, adding downward pressure from the sell-side amid already-missed revenue/EPS guidance in recent quarters. Analyst negativity can amplify selling when combined with legal headlines. HC Wainwright forecast

Hedge Funds Weigh In On REGENXBIO

Institutional investors and hedge funds have recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its position in REGENXBIO by 44.4% in the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 1,270 shares during the last quarter. Profund Advisors LLC raised its position in REGENXBIO by 11.8% during the 3rd quarter. Profund Advisors LLC now owns 14,444 shares of the biotechnology company’s stock worth $139,000 after buying an additional 1,523 shares during the last quarter. Deutsche Bank AG raised its position in REGENXBIO by 0.8% during the 4th quarter. Deutsche Bank AG now owns 192,582 shares of the biotechnology company’s stock worth $2,773,000 after buying an additional 1,527 shares during the last quarter. Captrust Financial Advisors lifted its stake in REGENXBIO by 13.2% during the 4th quarter. Captrust Financial Advisors now owns 15,228 shares of the biotechnology company’s stock valued at $219,000 after acquiring an additional 1,781 shares during the period. Finally, Pale Fire Capital SE lifted its stake in REGENXBIO by 7.7% during the 2nd quarter. Pale Fire Capital SE now owns 27,846 shares of the biotechnology company’s stock valued at $229,000 after acquiring an additional 2,000 shares during the period. 88.08% of the stock is owned by hedge funds and other institutional investors.

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.